Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants

Stable Identifier
R-HSA-9673767
Type
Pathway
Species
Homo sapiens
ReviewStatus
5/5
Locations in the PathwayBrowser
Expand all
General
SVG | 
PNG
Low
Medium
High
 | PPTX  | SBGN
Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
Click the image above or here to open this pathway in the Pathway Browser
PDGFRA is a type III transmembrane receptor tyrosine kinase. The extracellular domain consists of 5 immunoglobulin (IG) domains that contribute to dimerization and ligand binding. The intracellular region has a juxtamembrane domain that plays a role in autoinhibiting the receptor in the absence of ligand, and a bi-lobed kinase region with an activation loop and the catalytic cleft (reviewed in Klug et al, 2018). Upon ligand binding, PDGFRA undergoes dimerization and transautophosphorylation at at least 11 tyrosine residues in the intracellular domain. These phosphorylated residues are binding sites for downstream effectors of PDGFRA-responsive signaling pathways (reviewed in Klug et al, 2018; Roskoski, 2018).
PDGFRA is subject to activating mutations in a number of cancers, including gastrointestinal stromal tumors (GIST), melanoma and haematological cancers (reviewed in Corless et al, 2011; Wang et al, 2016; Roskoski, 2018). The most prevalent mutations in PDGFRA are at residue V561 in the juxtamembrane domain, N659 in the small lobe of the kinase domain and D842 in the activation loop of the kinase domain. PDGFRA is also subject to short deletions in the activation loop segment (reviewed in Roskoski, 2018). Acitvated forms of the protein may signal from the plasma membrane, similar to the wild type receptor, however there is also evidence that some mutants, notably D842V and V561D localize primarily to the Golgi membrane (Bahlawane et al, 2014). Activated PDGFRA mutants signal constitutively in the absence of ligand (reviewed in Roskoski, 2018; Wang et al, 2016; Klug et al, 2018).
Literature References
PubMed ID Title Journal Year
27170215 The platelet-derived growth factors (PDGFs) and their receptors (PDGFRs) are major players in oncogenesis, drug resistance, and attractive oncologic targets in cancer

Wang, Y, Appiah-Kubi, K, Wu, M, Yao, X, Qian, H, Wu, Y, Chen, Y

Growth Factors 2016
22089421 Gastrointestinal stromal tumours: origin and molecular oncology

Corless, CL, Barnett, CM, Heinrich, MC

Nat. Rev. Cancer 2011
29408302 The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders

Roskoski, R

Pharmacol. Res. 2018
25880691 Constitutive activation of oncogenic PDGFRα-mutant proteins occurring in GIST patients induces receptor mislocalisation and alters PDGFRα signalling characteristics

Bahlawane, C, Eulenfeld, R, Wiesinger, MY, Wang, J, Muller, A, Girod, A, Nazarov, PV, Felsch, K, Vallar, L, Sauter, T, Satagopam, VP, Haan, S

Cell Commun. Signal 2015
29964125 Structural and clinical consequences of activation loop mutations in class III receptor tyrosine kinases

Klug, LR, Kent, JD, Heinrich, MC

Pharmacol. Ther. 2018
Participants
Events
Participates
as an event of
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Cross References
Mondo
Authored
Rothfels, K  (2020-02-25)
Reviewed
Ip, CKM  (2020-02-06)
Created
Rothfels, K  (2020-01-08)
Cite Us!